{"id":39325,"date":"2025-09-02T19:57:09","date_gmt":"2025-09-02T19:57:09","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/39325\/"},"modified":"2025-09-02T19:57:09","modified_gmt":"2025-09-02T19:57:09","slug":"healthcare-packaging-company-nelipak-paid-e35m-dividend-before-seeking-staff-redundancies-the-irish-times","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/39325\/","title":{"rendered":"Healthcare packaging company Nelipak paid \u20ac35m dividend before seeking staff redundancies \u2013 The Irish Times"},"content":{"rendered":"<p class=\"c-paragraph paywall \">The Irish subsidiary of US healthcare packaging giant Nelipak paid a dividend of \u20ac35 million in its 2024 financial year, but sought up to 40 redundancies in an \u201coperational restructuring program\u201d at its Offaly plant in February.<\/p>\n<p class=\"c-paragraph paywall \">Nelipak generated more than \u20ac78.3 million in turnover from two of its medical packaging sites in the Republic of Ireland, \u20ac1.25 million more than in 2023. <\/p>\n<p class=\"c-paragraph paywall \">Despite this, rising production and administrative costs saw the company\u2019s profits reduce by nearly 29 per cent in the past year. Pretax profits fell from \u20ac9.9 million in 2023 to \u20ac7 million for the financial year ending in December 2024.<\/p>\n<p class=\"c-paragraph paywall \">The packaging company is involved in the design and production of custom packaging for medical devices and pharmaceutical products such as blisters packs, surgical procedure trays, pharmaceutical handling trays, and custom-built sealing machines.<\/p>\n<p class=\"c-paragraph paywall \">The majority of Nelipak\u2019s Irish production is for export, with \u20ac17.6 million in revenue coming from domestic sources.<\/p>\n<p class=\"c-paragraph paywall \">In 2024,  Nelipak  had \u20ac36.3 million in exports to non-European Union companies, with a further \u20ac21.6 million from other European countries, excluding the UK, which saw \u20ac2.8 million in exports.<\/p>\n<p class=\"c-paragraph paywall \">US-headquartered Nelipak, which was founded in the Netherlands in 1953, has more than 1,400 employees spread across 11 manufacturing sites.<\/p>\n<p class=\"c-paragraph paywall \">The company had an average of 261 employees in the Republic in 2024, a slight increase on the previous year\u2019s 256 staff, with the vast majority  in production roles. Total staff costs increased to \u20ac13.15 million in the past calendar year,  from \u20ac12.55 million in 2023.<\/p>\n<p class=\"c-paragraph paywall \">The company acquired Co Galway-based Plasmedics in 1995, before adding plants in Offaly and Derry,  following the acquisition of Bemis Healthcare Packaging Europe.<\/p>\n<p class=\"c-paragraph paywall \">The company began a programme of voluntary redundancies at its production plant in Clara, Co Offaly, at the start of 2025, seeking to eliminate 40 roles as part of a \u201crestructuring programme\u201d.<\/p>\n<p class=\"c-paragraph paywall \">\u201cIn order to align resources at the Nelipak Clara site with current production requirements, we have made the difficult decision to pursue an operational restructuring programme which will result in production staff reductions,\u201d Nelipak said  in February.<\/p>\n<p class=\"c-paragraph paywall \">The company said its Co Offaly site  \u201cremains among the largest of Nelipak\u2019s  11 global production sites\u201d and stressed  it is committed to \u201censuring that the Clara site is well-positioned for continued growth, investment and success in the coming years\u201d.<\/p>\n<p class=\"c-paragraph paywall \">Nelipak has been contacted for comment.<\/p>\n","protected":false},"excerpt":{"rendered":"The Irish subsidiary of US healthcare packaging giant Nelipak paid a dividend of \u20ac35 million in its 2024&hellip;\n","protected":false},"author":2,"featured_media":39326,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[18,1878,135,475,474,19,17,3171,2554],"class_list":{"0":"post-39325","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-eire","9":"tag-galway","10":"tag-health","11":"tag-health-care","12":"tag-healthcare","13":"tag-ie","14":"tag-ireland","15":"tag-offaly","16":"tag-pharma"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/39325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=39325"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/39325\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/39326"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=39325"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=39325"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=39325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}